# Nose to Brain CBD Nanocarriers for Dravet and Lennox Gastaut Syndromes

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/ced-nose-to-brain-cbd-nanocarriers-for-2026-09-21/
> **Published:** 2026-09-21T15:49:45-04:00 | **Last Modified / Clinically Audited:** 2026-10-01T12:33:19-04:00
> **Clinical Summary:** medical cannabis research: Physician review of Nanostructured lipid carriers for intranasal cannabidiol delivery in Dravet and Lennox-Gastaut syndromes: brid...

---

CED Clinical Relevance #88 Verified Clinical Evidence Primary literature analysis of Nanostructured lipid carriers for intranasal cannabidiol delivery in Dravet and Lennox-Gastaut syndromes: bridging preclinical promise to clinical translation.

Clinical Insight | CED Clinic
This article is best read as a translational roadmap, not as a treatment recommendation. Oral prescription cannabidiol already has randomized trial evidence for Dravet syndrome and Lennox Gastaut syndrome, but it is limited by variable absorption, delayed peak levels, hepatic metabolism, and drug interactions, especially with clobazam and valproate. Intranasal nanostructured lipid carriers are proposed to improve brain targeting and reduce systemic exposure. The clinical problem is real, yet the proposed solution has not crossed the pediatric evidence threshold. Families should not interpret this as proof that nasal CBD sprays are safer, faster, or more effective for seizure control.

Clinical SciencePeer-ReviewedDosing ContextSafety SignalsPhysician Insight

AudiencePatients, clinicians, healthcare providers, researchers, and policy analysts.
Primary TopicClinical study review: Nose to Brain CBD Nanocarriers for Dravet and Lenn.
Source[Read the full source](https://pubmed.ncbi.nlm.nih.gov/42751849/)

A new review argues that intranasal nanostructured lipid CBD could improve brain delivery for severe childhood epilepsies, but the concept remains preclinical and unproven in children.

What This Study Teaches Us
This review found preclinical evidence that intranasal nanostructured lipid carrier cannabidiol increases brain CBD exposure and brain-to-plasma ratios compared with free or oral CBD in animal models, with anticonvulsant activity reported in models such as pentylenetetrazol-induced seizures. It included 0 completed pediatric Dravet or Lennox Gastaut clinical trials, 0 human seizure-frequency endpoints, and no approved dosing schedule.

Why This Matters
For patient care, this distinction prevents families from confusing a delivery-platform hypothesis with an epilepsy treatment proven in children. If future studies confirm faster central exposure with lower systemic levels, intranasal NLC-CBD could change dosing strategy, rescue-use discussions, and interaction monitoring, but that remains unproven.

Study SnapshotPost TypePhysician-Guided Clinical Science Deep DivePrimary SourceTherapeutic deliveryPublication Date2026Sep17Evidence LevelJournal Article, ReviewFocus AreaNose to Brain CBD Nanocarriers for Dravet and Lennox GastautLead AuthorsYashika, Sachin Yadav, Anish Arora, Nisha Bharti et al.DOI10.1080/20415990.2026.2731738PMIDPMID: 42751849

Clinical Bottom Line
This study review translates complex data into practical clinical insights, maintaining realistic therapeutic expectations.

Headline vs. Reality Truth Meter | Clinical Analysis

**Mainstream Media Claim:** A nasal CBD nanomedicine could rapidly deliver cannabidiol to the brain and transform treatment for Dravet and Lennox Gastaut syndromes.

**Primary Journal Data:** The article is a narrative translational review of studies identified through PubMed, Scopus, Web of Science, and Google Scholar up to March 2026. It reports preclinical evidence that intranasal nanostructured lipid carrier CBD can increase brain exposure, improve brain-to-plasma ratios, and show anticonvulsant effects in animal seizure models, including pentylenetetrazol-induced convulsions. It reports no completed pediatric DS or LGS clinical trial, no human efficacy endpoint, and no validated clinical dosing regimen.

**Dr. Caplan’s Clinical Verdict:** Promising formulation science, but not a patient-ready epilepsy therapy. The correct clinical stance is curiosity with guardrails: continue evidence-based seizure care, consider prescription cannabidiol when appropriate, and wait for pediatric pharmacokinetic, safety, and efficacy trials before using intranasal NLC-CBD clinically.

Primary Analysis | Nanostructured lipid carriers for intran

**Study Overview:** Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) are severe developmental epileptic encephalopathies that appear in early childhood, are unresponsive to medications, and have a dismal neurodevelopmental prognosis. Most patients do not respond well to polytherapy, and the need to fulfill this gap in clinical practice is urgent. Cannabidiol (CBD) has proven to be an effective adjunct drug, but oral preparations have low bioavailability, slow onset and systemic adverse effects. Nanostructured lipid carriers (NLCs) are an innovative therapeutic technology that can deliver CBD directly to the brain via the nose, enhance brain targeting, achieve faster onset, and minimize systemic exposure, which could be a valuable solution to current deficiencies in treatment. Intranasal NLC-CBD has preclinical evidence of increasing brain CBD levels, facilitating anticonvulsant action, and protecting against seizures in established animal models, like pentylenetetrazol-induced convulsions. NLC-based preparations have increased brain-to-plasma ratios and longer central exposure at lower doses in comparison to free or orally administered CBD. Despite these promising findings, there are still translational gaps to be addressed, such as insufficient safety data in the long term, disease-specific DS/LGS genetic models, inconsistencies in the pediatric nasal physiology, and conventional clinical dosing paradigms. Literature for this review was identified through searches of PubMed, Scopus, Web of Science, and Google Scholar, covering studies published up to March 2026 on CBD, NLC, intranasal drug delivery, DS, and LGS.There is a dire need to carry out properly designed clinical trials that would demonstrate the safety, pharmacokinetics (PK) and efficacy of intranasal NLC-CBD in DS and LGS. The first pediatric clinical trials, adaptive trial models and regulatory harmonization are necessary to convert this noble nanomedicine approach into a clinical therapy. Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) are rare and severe forms of epilepsy which often start in childhood. A significant number of patients fail to respond to several antiseizure drugs, and have recurrent seizures. Cannabidiol (CBD) is a chemical found in the cannabis plant that is effective in reducing seizures, but there are some limitations in oral CBD products, including slow absorption and inconsistent efficacy and the possibility for drug interaction. In this review, a novel delivery system of delivering CBD to the brain via a nose spray containing nanostructured lipid carriers (NLCs) is investigated. The use of these tiny lipid-based particles can aid in the delivery of CBD to the brain more rapidly and effectively, avoiding the digestion process and lowering first-pass metabolism. Consequently, intranasal NLC-CBD is likely to have a quicker onset of effect, better brain penetration, and reduced doses. This review provides a summary of existing preclinical evidence, as well as safety and regulatory considerations and outlines the possible clinical development options for this technology. It also underscores some of the future possibilities, such as the application of artificial intelligence (AI), novel clinical trial designs, and combination therapies. While additional clinical trials are necessary, intranasal NLC-CBD is a promising approach for better seizure control, quality of life and treatment ease for DS and LGS patients and their caregivers.

**Primary Source & Scope:** Published in *Therapeutic delivery* (2026Sep17) conducted by Yashika, Sachin Yadav, Anish Arora, Nisha Bharti et al. [Primary Source Link](https://pubmed.ncbi.nlm.nih.gov/42751849/) | **Primary Record:** DOI: 10.1080/20415990.2026.2731738 | PMID: 42751849

How Strong Is This Evidence?
The evidence strength is early translational and hypothesis-generating. The review synthesizes formulation, pharmacokinetic, and animal seizure-model data, but it is not a randomized clinical trial, not a meta-analysis of pediatric outcomes, and not a pharmacokinetic study in children with DS or LGS. Its strongest contribution is mapping plausible mechanisms and development requirements rather than demonstrating clinical efficacy.

Where This Paper Deserves Skepticism
Preclinical nose-to-brain delivery can overestimate clinical performance because rodents and children differ substantially in nasal surface area, olfactory anatomy, mucociliary clearance, inflammation, and administration behavior. Publication bias is also possible, since positive nanocarrier studies are more likely to appear than failed formulations. Disease-specific genetic models of Dravet and Lennox Gastaut, chronic toxicity data, and interaction studies with common antiseizure regimens remain insufficient.

What This Paper Does Not Show
This review does not prove that intranasal NLC-CBD reduces seizures in children with Dravet syndrome or Lennox Gastaut syndrome. It also does not establish that compounded nasal CBD products, commercial wellness sprays, or nonprescription cannabinoid formulations are equivalent to a rigorously manufactured nanostructured lipid carrier medicine.

How This Fits With the Broader Clinical Conversation

Clinical research into Nanostructured lipid carriers for intranasal canna is progressing through rigorously documented peer-reviewed cohorts.

Evaluating primary evidence enables clinicians to tailor care plans while respecting therapeutic boundaries.

Dr. Caplan’s Take

*The clinically attractive idea here is not simply cannabidiol, since prescription oral CBD already has a role in Dravet syndrome and Lennox Gastaut syndrome. The important proposal is route and formulation: a lipid nanocarrier administered through the nose may bypass part of gastrointestinal variability and first-pass metabolism, potentially producing more efficient central nervous system exposure. That could matter for children whose seizure burden remains high despite polytherapy, and for families navigating sedation, appetite changes, diarrhea, transaminase elevation, and antiseizure drug interactions.*

*But this paper does not let us prescribe around those problems yet. Animal seizure models, improved brain-to-plasma ratios, and longer central exposure are mechanistic signals, not pediatric outcomes. The major unanswered questions are practical and clinical: nasal tolerability in young children, reproducible dosing during congestion or crying, chronic mucosal safety, developmental pharmacokinetics, device performance, caregiver technique, and whether seizure frequency, drop attacks, status epilepticus risk, sleep, cognition, and quality of life actually improve.*

What a Careful Reader Should Take Away
Intranasal NLC-CBD is a credible research direction, not a current substitute for established DS or LGS epilepsy care. Families should discuss prescription CBD, drug interactions, and seizure action plans with a specialist rather than experimenting with nasal cannabinoid products.

Evidence Interpretation Guide

Table of Contents

- [How to Interpret This Clinical Study](#How_to_Interpret_This_Clinical_Study)[Three Rules for Critical Reading](#Three_Rules_for_Critical_Reading)
- [CED Perspective Lens: Eight Clinical Viewpoints](#CED_Perspective_Lens_Eight_Clinical_Viewpoints)[Clinical Evidence Synthesis](#Clinical_Evidence_Synthesis)
- [Patient Communication](#Patient_Communication)
- [Dosing & Formulations](#Dosing_Formulations)
- [Safety & Side Effect Profile](#Safety_Side_Effect_Profile)
- [Regulatory & Policy Dynamics](#Regulatory_Policy_Dynamics)
- [Mechanisms & Physiology](#Mechanisms_Physiology)
- [Research Limitations](#Research_Limitations)
- [Future Outlook](#Future_Outlook)
- [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related)

## How to Interpret This Clinical Study

Navigating biomedical publications regarding Nanostructured lipid carriers for intranasal requires reviewing study methodology and patient eligibility.

### Three Rules for Critical Reading

**Separate formulation promise from clinical proof**animal brain-exposure data do not establish seizure reduction in children.

**Compare against the correct standard**approved oral purified CBD has clinical trial evidence, while intranasal NLC-CBD does not yet.

**Critical Rule**Look for pediatric pharmacokinetics, chronic nasal safety, drug interaction data, and validated seizure endpoints before changing care.

Key Evaluation Question
Does the evidence show that intranasal NLC-CBD improves clinically meaningful DS or LGS outcomes in children, or only that it improves delivery metrics in preclinical models?

The Patient Question
Should my child be considered for approved prescription CBD now, and what monitoring is needed with our current antiseizure medications?

The Bottom Line
The paper identifies a plausible next-generation CBD delivery strategy, but it does not justify clinical use of nasal CBD nanocarriers for DS or LGS outside regulated research.

CED Perspective Lens

## CED Perspective Lens: Eight Clinical Viewpoints

Analyzing evidence across clinical, patient, safety, dosing, and physiological perspectives

Lens OverviewEight structured clinical perspectives synthesizing primary study data for patient care.

#### Clinical Evidence Synthesis

The review gathers preclinical and formulation evidence for intranasal nanostructured lipid carrier CBD in severe developmental epileptic encephalopathies. Its central claim is pharmacologic plausibility: lipid particles may improve CBD solubility, protect the molecule, and increase brain exposure after nasal administration.

The evidence stops before clinical confirmation. No completed pediatric DS or LGS trial is reported, and no human seizure-reduction endpoint is available. Oral purified CBD remains the cannabinoid formulation with randomized clinical evidence in these syndromes.

Lens takeawayThis is a promising delivery concept, not proof of clinical seizure benefit.

#### Patient Communication

Families facing Dravet or Lennox Gastaut syndrome often hear about novel CBD delivery as a hopeful solution. The honest message is that the medical need is urgent, but scientific enthusiasm must not outrun pediatric safety testing.

Clinicians should explain the difference between prescription oral CBD, research-grade intranasal nanocarriers, and consumer nasal cannabinoid products. They are not interchangeable. Seizure plans, rescue medications, and interaction monitoring remain central. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines.

Lens takeawayHope is appropriate, but families need clear boundaries around unapproved nasal CBD.

#### Dosing & Formulations

The review suggests that intranasal NLC-CBD could produce higher brain exposure at lower doses than conventional CBD approaches. That does not translate into a pediatric milligram dose, a spray count, or a home titration schedule.

For current clinical practice, dosing decisions should remain anchored to approved oral purified CBD when indicated, body weight, liver function, concomitant drugs, and seizure response. Nasal nanocarrier dosing requires formal pharmacokinetic trials. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines.

Lens takeawayDo not convert oral CBD doses into nasal nanocarrier doses without trials.

#### Safety & Side Effect Profile

Lower systemic exposure is a theoretical advantage, but it is not yet a demonstrated safety outcome in children. Chronic nasal use raises its own questions: mucosal irritation, smell disturbance, local inflammation, and absorption variability.

Systemic cannabinoid issues also remain possible. CBD can interact with clobazam, valproate, and other antiseizure medicines, and may affect sedation, appetite, diarrhea, and liver enzymes depending on exposure. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines.

Lens takeawayA targeted route may reduce some risks, but it creates new safety questions.

#### Regulatory & Policy Dynamics

A pediatric nasal nanomedicine would need far more than cannabinoid permissibility. Regulators would expect manufacturing consistency, particle-size control, sterility or microbial standards, device validation, pediatric pharmacokinetics, and chronic toxicology.

Access claims should therefore be restrained. Even if future trials succeed, an NLC-CBD nasal product would likely be regulated as a specific drug-device formulation, not as a general cannabis product. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines.

Lens takeawayRegulatory approval would depend on product-specific evidence, not CBD familiarity.

#### Mechanisms & Physiology

The proposed mechanism involves nasal deposition, mucosal absorption, possible olfactory or trigeminal pathway transport, and lipid-carrier enhancement of CBD stability and penetration. These features could increase central nervous system delivery.

CBD itself has complex antiseizure biology and does not act like intoxicating THC. Potential mechanisms include modulation of excitability, inflammation, calcium signaling, and neurotransmitter balance, but clinical benefit must still be measured. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines.

Lens takeawayMechanistic plausibility supports trials, but mechanisms cannot replace patient outcomes.

#### Research Limitations

The largest limitation is translational distance. Animal seizure models, including chemically induced convulsions, do not fully reproduce Dravet genetics, Lennox Gastaut network pathology, developmental trajectories, or polytherapy in children.

Nasal physiology also varies by age, illness, congestion, anatomy, and administration technique. These factors could meaningfully alter delivered dose, especially in young children with neurologic disability. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines.

Lens takeawayThe formulation may work in models yet perform differently in real children.

#### Future Outlook

The next studies should start with adult or adolescent safety where appropriate, then carefully designed pediatric pharmacokinetic trials. Investigators need dose proportionality, brain-exposure proxies, nasal tolerability, and interaction data.

Efficacy trials should measure seizure frequency, responder rates, rescue medication use, caregiver burden, sleep, cognition, and adverse events. Adaptive designs may help rare-disease research, but endpoints must remain clinically meaningful. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines.

Lens takeawayThe pathway forward is clear: safety, pharmacokinetics, then meaningful seizure outcomes.

Join the Conversation

Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan)

Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/)

 

 
 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 

 
 Physician-Led, Whole-Person Care
 A doctor who takes the time to truly understand you.
 Personal care that starts with listening and is guided by experience and ingenuity.

 
 Health, Longevity, Wellness
 One-on-One Cannabis Guidance
 Metabolic Balance
 

 
 [Leave a Message](https://cedclinic.com/contact/)
 [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
 [Medical Consulting](https://cedclinic.com/book/)
 [Cannabis Care](https://cedclinic.com/book/)
 
 

 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 
 

Share this Evidence Watch

[X](https://twitter.com/intent/tweet?text=Nose+to+Brain+CBD+Nanocarriers+for+Dravet+and+Lennox+Gastaut+Syndromes&url=https%3A%2F%2Fcedclinic.com%2Fced-nose-to-brain-cbd-nanocarriers-for--2026-09-21%2F)
[LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fced-nose-to-brain-cbd-nanocarriers-for--2026-09-21%2F)
[BlueSky](https://bsky.app/intent/compose?text=Nose+to+Brain+CBD+Nanocarriers+for+Dravet+and+Lennox+Gastaut+Syndromes%20https%3A%2F%2Fcedclinic.com%2Fced-nose-to-brain-cbd-nanocarriers-for--2026-09-21%2F)
[Instagram](https://www.instagram.com/drcaplan/)
[Substack](https://doctorapprovedcannabis.substack.com/)
[RSS](https://cedclinic.com/feed/)

Source: [Primary Source: Nanostructured lipid carriers for intranasal cannabidiol delivery in Dravet and Lennox-Gastaut syndromes: bridging preclinical promise to clinical translation.](https://pubmed.ncbi.nlm.nih.gov/42751849/)

Related Reading at CED ClinicContinue exploring the evidence[CED Clinic Medical Cannabis Education](https://cedclinic.com/about-us/education/)

Explore clinical guides, dosing frameworks, and patient resources from Dr. Caplan.

[Read Clinical Resources](https://cedclinic.com/about-us/education/)[Understanding Cannabis Dosing and Ratios](https://cedclinic.com/topic-dosage/)

A clinical overview of cannabinoid titration and administration methods for patient care.

[View Dosing Guide](https://cedclinic.com/topic-dosage/)[Latest Medical Science and Research Reviews](https://cedclinic.com/category/cannabis-science/)

Browse CED Clinic’s archive of peer-reviewed study deep dives.

[Browse Science Archive](https://cedclinic.com/category/cannabis-science/)

## Frequently Asked Questions

Is intranasal NLC-CBD available now for Dravet or Lennox Gastaut syndrome?

No. The review describes a research strategy and preclinical evidence, not an approved pediatric therapy. Families should not substitute nasal CBD products for prescribed antiseizure treatment.

How is this different from prescription oral CBD?

Prescription oral CBD is an approved, standardized formulation with randomized trial evidence for certain severe epilepsies. Intranasal NLC-CBD is a proposed nanocarrier delivery system intended to improve brain targeting, but it lacks completed pediatric efficacy trials.

Does this review prove nasal CBD works faster?

No. Preclinical data suggest the possibility of faster or more efficient brain delivery, but human onset, duration, and seizure-response timing have not been established in DS or LGS.

Could nasal delivery reduce CBD side effects?

Possibly, but this remains theoretical. If systemic exposure is lower, some systemic side effects might decrease, but nasal irritation, variable absorption, and persistent drug interactions could still occur.

Can families use over-the-counter nasal CBD sprays instead?

No. Consumer nasal CBD products are not equivalent to a pharmaceutical nanostructured lipid carrier formulation. They may have inconsistent potency, contaminants, poor mucosal safety data, and no DS or LGS efficacy evidence.

What safety tests are most important before pediatric use?

Key studies include nasal mucosal safety, chronic exposure toxicology, pediatric pharmacokinetics, liver enzyme monitoring, sedation assessment, and interaction testing with drugs such as clobazam and valproate.

Why are Dravet and Lennox Gastaut syndromes so difficult to treat?

They are developmental epileptic encephalopathies with early onset, multiple seizure types, high medication resistance, cognitive and behavioral burden, and frequent need for multidrug therapy.

What outcomes should future trials measure?

Trials should measure seizure frequency, responder rate, drop seizures where relevant, rescue medication use, adverse events, liver enzymes, sleep, cognition, caregiver burden, and quality of life.

Would intranasal NLC-CBD be a rescue medication?

That is unknown. Faster delivery could make rescue-use research interesting, but no study has shown that intranasal NLC-CBD safely stops seizure clusters or status epilepticus in children.

What should patients discuss with their clinician today?

Discuss whether approved oral CBD is appropriate, how it interacts with current antiseizure drugs, what monitoring is needed, and why experimental nasal CBD should wait for regulated clinical trials.

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).